TCT 2015: More TAVR Results, Super-Thin Strut Stents, And Percutaneous Heart Pumps
Clinical trials of transcatheter aortic valve technologies once again dominated news coming out of the Transcatheter Cardiovascular Therapeutics conference, held this year in San Francisco, October 10–15. But the meeting also featured new coronary stent technologies and new information on percutaneous heart pumps to support patients during difficult interventions.
You may also be interested in...
In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions, and suspensions over the last month. This edition, which looks at trial updates from Oct. 5 through to Nov. 4, highlights the small innovators developing bioresorbable stents for cardio- and peripheral vascular disease.
Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.